| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
GABA-A receptor benzodiazepine site (positive allosteric modulator). Flutazolam binds to the benzodiazepine site on GABA-A receptors, enhancing the inhibitory effects of GABA. This increases chloride conductance and hyperpolarizes neurons, producing anxiolytic, sedative, and muscle relaxant effects. It is a positive allosteric modulator of the GABA-A receptor.
|
|---|---|
| ln Vitro |
Long-term isolation mice's pentylenetetrazole convulsions, fighting behavior, and hyperemotionality are all inhibited by MS-4101, which also improves thiopental sleep. Diazepam's effects are comparable to those of MS-4101. Mice's scratching and head twitching caused by mescaline are greatly reduced by MS-4101 [1].
In vitro, Flutazolam binds to the benzodiazepine site on GABA-A receptors with high affinity. It competes with [³H]flumazenil or [³H]flunitrazepam for binding to GABA-A receptors in brain membrane preparations. It enhances GABA-induced chloride currents in electrophysiological assays. It is more potent than diazepam in reducing spontaneous locomotor activity in some assays. |
| ln Vivo |
In vivo, Flutazolam exhibits anxiolytic, sedative, and muscle relaxant effects in animal models. It is used clinically for anxiety and psychosomatic disorders. It has gastrointestinal effects and is used for chronic gastritis and irritable bowel syndrome. It has a relatively short half-life and active metabolites.
|
| Enzyme Assay |
GABA-A receptor binding assay: Rat brain membranes are incubated with [³H]flunitrazepam (1 nM) and varying concentrations of Flutazolam. Non-specific binding is defined with diazepam. Reactions are incubated at 4°C for 90 minutes, terminated by filtration, and radioactivity counted. Ki values are calculated by Cheng-Prusoff equation.
|
| Cell Assay |
Electrophysiological assay: Recombinant GABA-A receptors are expressed in Xenopus oocytes or HEK293 cells. GABA-induced chloride currents are recorded using two-electrode voltage clamp or patch clamp. Flutazolam is co-applied with GABA at varying concentrations. Potentiation of GABA response is quantified.
|
| Animal Protocol |
In vivo anxiolytic assay: Mice or rats are tested in the elevated plus maze, light-dark box, or conflict test. Flutazolam is administered intraperitoneally or orally at various doses. Anxiolytic-like activity is assessed by increased open arm exploration or punished responding. Sedative effects are measured by locomotor activity. Muscle relaxant effects are assessed by rotarod test.
|
| References |
[1]. Mitsushima T, et al. Psychopharmacological effects of flutazolam (MS-4101). Nihon Yakurigaku Zasshi. 1978 Nov;74(8):959-79.
|
| Additional Infomation |
Flutazolam is an organic molecular entity and a hemiacetal ether.
|
| Molecular Formula |
C19H18CLFN2O3
|
|---|---|
| Molecular Weight |
376.8124
|
| Exact Mass |
376.099
|
| CAS # |
27060-91-9
|
| PubChem CID |
3398
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.47g/cm3
|
| Boiling Point |
601.9ºC at 760mmHg
|
| Flash Point |
317.8ºC
|
| Vapour Pressure |
2.44E-15mmHg at 25°C
|
| Index of Refraction |
1.672
|
| LogP |
2.354
|
| tPSA |
53.01
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
539
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(CCO)C2=CC=C(Cl)C=C2C(OCC3)(C4=CC=CC=C4F)N3C1
|
| InChi Key |
WMFSSTNVXWNLKI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18ClFN2O3/c20-13-5-6-17-15(11-13)19(14-3-1-2-4-16(14)21)22(8-10-26-19)12-18(25)23(17)7-9-24/h1-6,11,24H,7-10,12H2
|
| Chemical Name |
10-chloro-11b-(2-fluorophenyl)-7-(2-hydroxyethyl)-3,5-dihydro-2H-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
|
| Synonyms |
MS-4101 Coreminal FlutazolamRo 7-6102
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6539 mL | 13.2693 mL | 26.5386 mL | |
| 5 mM | 0.5308 mL | 2.6539 mL | 5.3077 mL | |
| 10 mM | 0.2654 mL | 1.3269 mL | 2.6539 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.